5 research outputs found
Volumetric and MGMT parameters in glioblastoma patients: Survival analysis
Abstract Background In this study several tumor-related volumes were assessed by means of a computer-based application and a survival analysis was conducted to evaluate the prognostic significance of pre- and postoperative volumetric data in patients harboring glioblastomas. In addition, MGMT (O6-methylguanine methyltransferase) related parameters were compared with those of volumetry in order to observe possible relevance of this molecule in tumor development. Methods We prospectively analyzed 65 patients suffering from glioblastoma (GBM) who underwent radiotherapy with concomitant adjuvant temozolomide. For the purpose of volumetry T1 and T2-weighted magnetic resonance (MR) sequences were used, acquired both pre- and postoperatively (pre-radiochemotherapy). The volumes measured on preoperative MR images were necrosis, enhancing tumor and edema (including the tumor) and on postoperative ones, net-enhancing tumor. Age, sex, performance status (PS) and type of operation were also included in the multivariate analysis. MGMT was assessed for promoter methylation with Multiplex Ligation-dependent Probe Amplification (MLPA), for RNA expression with real time PCR, and for protein expression with immunohistochemistry in a total of 44 cases with available histologic material. Results In the multivariate analysis a negative impact was shown for pre-radiochemotherapy net-enhancing tumor on the overall survival (OS) (p = 0.023) and for preoperative necrosis on progression-free survival (PFS) (p = 0.030). Furthermore, the multivariate analysis confirmed the importance of PS in PFS and OS of patients. MGMT promoter methylation was observed in 13/23 (43.5%) evaluable tumors; complete methylation was observed in 3/13 methylated tumors only. High rate of MGMT protein positivity (> 20% positive neoplastic nuclei) was inversely associated with pre-operative tumor necrosis (p = 0.021). Conclusions Our findings implicate that volumetric parameters may have a significant role in the prognosis of GBM patients. Furthermore, volumetry could help not only to improve the prediction of outcome but also the outcome itself by identifying patients at high risk of treatment failure and, thus, seek alternative treatment for these patients. In this small series, MGMT protein was associated with less aggressive tumor characteristics.</p
STAT-Related Profiles Are Associated with Patient Response to Targeted Treatments in Locally Advanced SCCHN
AbstractThe anti-epidermal growth factor receptor antibody cetuximab (Erbitux, CTX) is currently used for the treatment of locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN), as yet with modest effectiveness, prompting for the identification of response predictors to this treatment and for the targeting of additional pathways implicated in this disease. Within this scope, we investigated the effect of SRC/STAT pathway components on LA-SCCHN patient outcome. SRC, STAT1, STAT3, STAT5A, STAT5B, ANXA1, CAV1, IGFBP2, EPHA2, EPHB2, and MSN relative gene expression, as well as Stat protein activation, were assessed on LA-SCCHN tumor tissues from 35 patients treated with combined radiotherapy (RT) and CTX-based regimens. Stat1, Stat3, and Stat5 proteins were usually found activated in neoplastic nuclei (70.4%, 85.7%, and 70.8%, respectively). Activated Stat3 and Stat5 were associated with each other (P = .017) and with a CAV1high/MSNhigh/IGFBP2low profile. All patients with tumors expressing high STAT5A/EPHA2 experienced a complete response on RT-CTX-based treatments (12/15 complete responders, P < .0001) and a longer progression-free survival (P = .024). Few tumors expressed high ANXA1/CAV1/EPHA2 and low IGFBP2, a putative dasatinib response-related profile, whereas high ANXA1 was associated with shorter overall survival (P = .003). In conclusion, Stat activation is common in LA-SCCHN, where overexpression of STAT5A and EPHA2 may predict for response to RT-CTX treatments. The STAT5A/EPHA2 profile seems of particular interest for validation in larger cohorts and in multiple tumor types because markers for the positive selection of patients to benefit from CTX-containing treatments are currently lacking
STAT-Related Profiles Are Associated with Patient Response to Targeted Treatments in Locally Advanced SCCHN
The anti-epidermal growth factor receptor antibody cetuximab (Erbitux,
CTX) is currently used for the treatment of locally advanced squamous
cell carcinoma of the head and neck (LA-SCCHN), as yet with modest
effectiveness, prompting for the identification of response predictors
to this treatment and for the targeting of additional pathways
implicated in this disease. Within this scope, we investigated the
effect of SRC/STAT pathway components on LA-SCCHN patient outcome. SRC,
STAT1, STAT3, STAT5A, STAT5B, ANXA1, CAV1, IGFBP2, EPHA2, EPHB2, and MSN
relative gene expression, as well as Stat protein activation, were
assessed on LA-SCCHN tumor tissues from 35 patients treated with
combined radiotherapy (RT) and CTX-based regimens. Stat1, Stat3, and
Stat5 proteins were usually found activated in neoplastic nuclei
(70.4%, 85.7%, and 70.8%, respectively). Activated Stat3 and Stat5
were associated with each other (P = .017) and with a
CAV1(high)/MSNhigh/IGFBP2(low) profile. All patients with tumors
expressing high STAT5A/EPHA2 experienced a complete response on
RT-CTX-based treatments (12/15 complete responders, P < .0001) and a
longer progression-free survival (P = .024). Few tumors expressed high
ANXA1/CAV1/EPHA2 and low IGFBP2, a putative dasatinib response-related
profile, whereas high ANXA1 was associated with shorter overall survival
(P = .003). In conclusion, Stat activation is common in LA-SCCHN, where
overexpression of STAT5A and EPHA2 may predict for response to RT-CTX
treatments. The STAT5A/EPHA2 profile seems of particular interest for
validation in larger cohorts and in multiple tumor types because markers
for the positive selection of patients to benefit from CTX-containing
treatments are currently lacking